These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29756563)

  • 1. Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases.
    Ferrer MD; Busquets-Cortés C; Capó X; Tejada S; Tur JA; Pons A; Sureda A
    Curr Med Chem; 2019; 26(18):3225-3241. PubMed ID: 29756563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
    Bertolini A; Ottani A; Sandrini M
    Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
    Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
    Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
    Everts B; Währborg P; Hedner T
    Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.
    Meshram MA; Bhise UO; Makhal PN; Kaki VR
    Eur J Med Chem; 2021 Dec; 225():113804. PubMed ID: 34479036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.
    Rao P; Knaus EE
    J Pharm Pharm Sci; 2008 Sep; 11(2):81s-110s. PubMed ID: 19203472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade.
    Sala A; Proschak E; Steinhilber D; Rovati GE
    Biochem Pharmacol; 2018 Dec; 158():161-173. PubMed ID: 30315753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
    Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
    Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PGE synthase inhibitors as an alternative to COX-2 inhibitors.
    Jachak SM
    Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.
    Graham GG; Davies MJ; Day RO; Mohamudally A; Scott KF
    Inflammopharmacology; 2013 Jun; 21(3):201-32. PubMed ID: 23719833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
    Fiorucci S; Meli R; Bucci M; Cirino G
    Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural COX-2 Inhibitors as Promising Anti-inflammatory Agents: An Update.
    Cui J; Jia J
    Curr Med Chem; 2021; 28(18):3622-3646. PubMed ID: 32942970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase isoforms and atherosclerosis.
    Belton O; Fitzgerald DJ
    Expert Rev Mol Med; 2003 Mar; 5(9):1-18. PubMed ID: 14987412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 in inflammation and resolution.
    Rajakariar R; Yaqoob MM; Gilroy DW
    Mol Interv; 2006 Aug; 6(4):199-207. PubMed ID: 16960142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S; Distrutti E
    Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors.
    Wang R; Guo L; Wang P; Yang W; Lu Y; Huang Z; Tang C
    Curr Pharm Des; 2013; 19(1):115-25. PubMed ID: 22950494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers.
    Khanapure SP; Garvey DS; Janero DR; Letts LG
    Curr Top Med Chem; 2007; 7(3):311-40. PubMed ID: 17305573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.